Grant: Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
University of Toronto
$100,000.00
Functional Genomic Analysis of Fungal Virulence Genes and Genetic Networks
FY 2014-15
Summary
The impact of fungal pathogens on human health is devastating. They infect billions of people around the globe, and kill more than 1.5 million each year. The most vulnerable are people with reduced immune function, such as those with HIV or those undergoing immune suppressing treatments for cancer or organ transplants. One fungal pathogen kills more humans than any other, and this is Candida albicans. It kills almost 50% of people suffering from bloodstream infections. Treating these infections is extremely difficult, as fungi are closely related to humans and there are very few drugs that kill the fungus but not the host. With the emergence of drug resistance, it is now critical to develop new therapeutic strategies. To address this important clinical need and identify new drug targets, it is critical to uncover the mechanisms that allow this pathogen to cause life-threatening human disease.
We are one of the first academic labs to obtain a powerful resource that will allow us to test the function of each gene in the C. albicans genome. Through collaboration with a pharmaceutical company, we now have a library of mutants covering almost every C. albicans gene. This resource provides an unprecedented opportunity to dissect which genes contribute to the disease process, and to further determine how they do so. We will use this platform to characterize the impact of reducing the dosage of each gene on growth and cellular physiology in order to identify genes that are essential for growth of the pathogen. Further, we will screen the library to identify genes that interact with known drug targets and regulators of the disease process. Ultimately, we will decipher how specific genes influence the disease process by monitoring growth of each mutant in the context of human immune cells, as well as mouse models of C. albicans infection. This research will reveal new strategies to cripple the pathogen and drug targets to improve clinical outcome for millions of people.
Department
Program
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
329950
Name
Cowen Leah E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Genomics: Systems and computational biology
Projecttitle
Functional Genomic Analysis of Fungal Virulence Genes and Genetic Networks
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Keyworddelim
Antifungal Drug Target Identification; Candida Albicans; Chemical Genomics; Essential Gene Function; Functional Genomics; Fungal Morphogenesis; Fungal Pathogenesis; Haploinsufficiency Profiling; Microbial Genomics; Next Generation Sequencing
Abstract
The impact of fungal pathogens on human health is devastating. They infect billions of people around the globe, and kill more than 1.5 million each year. The most vulnerable are people with reduced immune function, such as those with HIV or those undergoing immune suppressing treatments for cancer or organ transplants. One fungal pathogen kills more humans than any other, and this is Candida albicans. It kills almost 50% of people suffering from bloodstream infections. Treating these infections is extremely difficult, as fungi are closely related to humans and there are very few drugs that kill the fungus but not the host. With the emergence of drug resistance, it is now critical to develop new therapeutic strategies. To address this important clinical need and identify new drug targets, it is critical to uncover the mechanisms that allow this pathogen to cause life-threatening human disease.
We are one of the first academic labs to obtain a powerful resource that will allow us to test the function of each gene in the C. albicans genome. Through collaboration with a pharmaceutical company, we now have a library of mutants covering almost every C. albicans gene. This resource provides an unprecedented opportunity to dissect which genes contribute to the disease process, and to further determine how they do so. We will use this platform to characterize the impact of reducing the dosage of each gene on growth and cellular physiology in order to identify genes that are essential for growth of the pathogen. Further, we will screen the library to identify genes that interact with known drug targets and regulators of the disease process. Ultimately, we will decipher how specific genes influence the disease process by monitoring growth of each mutant in the context of human immune cells, as well as mouse models of C. albicans infection. This research will reveal new strategies to cripple the pathogen and drug targets to improve clinical outcome for millions of people.
Competitiondate
201503
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cowen, Leah E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~